40 Paul Tudor Jones II Lilly(Eli) & Trades
Paul Tudor Jones II's position in Lilly(Eli) & is currently worth $59.7 Million. That's 0.74% of their equity portfolio (7th largest holding). The first Lilly(Eli) & trade was made in Q2 2013. Since then Paul Tudor Jones II bought shares 27 more times and sold shares on 24 occasions. The stake costed the investor $45.6 Million, netting the investor a gain of 31% so far.
News about Lilly(Eli) & Co and Paul Tudor Jones II
Eli Lilly and : Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance® (empagliflozin) on risk of heart failure hospitalization and death in adults following a heart attack
… -Metabolic Medicine, Boehringer Ingelheim Pharmaceuticals , Inc. "Building … side effects of prescription drugs to the FDA. … 2023 Boehringer Ingelheim and...
Alzheimer’s disease market expected to reach $14B globally in 2030
Driven by novel drugs from Biogen (BIIB) and Eli Lilly (LLY), the Alzheimer’s disease market will hit $13.7B in 2030, according to a new industry report. Rea...
Eli Lilly: Jardiance Improves Overall Blood Sugar Control In Children With Type 2 Diabetes
INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) said the DINAMO phase III clinical trial met its primary endpoint by showing a statistically significant...